日本久久久久精品免费网播放,国产精品每日更新在线观看,久久中文字幕亚洲精品第一区,成人H视频在线观看,日韩一区二区三区在线播放,国产免费一区二区三区香蕉精,色综合天天天天做夜夜夜夜做,草久免费午夜福利,伊人久久大香线蕉成人,亚洲伊人久久大香线蕉综合

WE Initiate Science & Technology Value,
Always for Caring

WESTVAC

Media > Company News

Selection of China's Top 10 Advances for 2023 in Medical Biotechnology Announced, WestVac Biopharma/Sichuan University West China Hospital's New COVID-19 Vaccine Successfully Selected
2024-01-14
On January 13, 2024, the results of the selection for the top 10 medical biotechnology advances in China for 2023, organized by the China Medicinal Biotechnology Association and the journal "Chinese Medicinal Biotechnology" were announced. The Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell) and Recombinant COVID-19 (XBB) Trimeric Protein Vaccine (Sf9 Cell) jointly developed by WestVac Biopharma and Sichuan University West China Hospital stood out in numerous rounds of evaluation and was successfully selected as the "Top 10 Advances in Chinese Medical Biotechnology of the Year" in China!


It’s reported that the "Top 10 Advances in Chinese Medical Biotechnology of the Year" is organized by the China Medicinal Biotechnology Association and the journal "Chinese Medicinal Biotechnology". It has been held continuously for nine years, focusing on showcasing the latest annual advances and breakthroughs in the field of medical biotechnology in China. The selection process for the Top 10 Advances in Chinese Medical Biotechnology for 2023 involved six stages: recommendation and application, preliminary expert review, public voting, academician examination by letter, expert review, and press release.

The Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell), known as Coviccine® Trivalent XBB Vaccine is the first internationally approved COVID-19 vaccine containing XBB.1.5. It is a new generation of broad-spectrum COVID-19 vaccine of high purity and high quality produced by WestVac Biopharma, taking advantage of the fast-response of the internationally advanced technology platform of recombinant protein vaccine production from insect cells. The Coviccine® Trivalent XBB Vaccine was granted emergency use approval by relevant national departments in June 2023 and has been administered free of charge in more than 300 cities and over 10,000 community vaccination sites nationwide through multiple rounds of vaccinations.